BioPharmSignal logoBioPharmSignal

Biotech News

Biote Reports Third Quarter 2025 Financial Results

biote Corp (BTMD)biote CorpEarnings

Continued progress against strategic priorities Repurchased approximately one million shares of Class A common stock Reiterates 2025 financial guidance Third Quarter 2025 Financial Highlights Revenue of $48.0 million Gross profit margin of 71.8% Net income of $9.2 million and diluted earnings per

Related news

BTMDbiote Corp2025-10-22 20:05 EST

Biote Schedules Third Quarter 2025 Financial Results Release and Conference Call

BTMDbiote Corp2026-08-05 20:05 EST

Biote Reports Second Quarter 2026 Financial Results

View all latest news

biote Corp

Hormone Optimization Biote operates a practitioner-led platform focused on hormone optimization and healthy aging. Its principal offering uses bioidentical hormone pellets implanted during office-based procedures. Practitioner Network The company trains and certifies medical practitioners, supplies procedure products and supports clinics...

Recent company news

BTMDbiote Corp2026-08-05 20:05 EST

Biote Reports Second Quarter 2026 Financial Results

BTMDbiote Corp2026-07-22 20:05 EST

Biote Schedules Second Quarter 2026 Financial Results Release and Conference Call

BTMDbiote Corp2026-06-01 12:00 EST

Biote Appoints Komal Bajaj, MD, MS as Chief Medical Officer

BTMDbiote Corp2026-05-28 13:00 EST

Biote Names Bob Peterson, Current Chief Financial and Chief Business Officer, as Interim CEO

BTMDbiote Corp2026-05-06 20:05 EST

Biote Reports First Quarter 2026 Financial Results

Stock data

Close
1.61 USD
Market cap
65.21M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States